Office for Human Research Trials
David LePay, MD/PhD, will head the new office as senior advisor for clinical science. LePay had been on detail as acting senior advisor for clinical science in the Office of Science Coordination and Communication while establishing the new office (1"The Pink Sheet" March 26, p. 28)
You may also be interested in...
FDA's draft guidance on data safety monitoring boards will address when clinical trials should be stopped for safety or efficacy reasons.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials